Early conversion to belatacept-based immunosuppression regimen promotes improved long-term renal graft function in kidney transplant recipients
- 29 June 2023
- journal article
- research article
- Published by Elsevier in Transplant Immunology
- Vol. 80, 101882
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Clinical consequences of circulating CD28-negative T cells for solid organ transplantationTransplant International, 2015
- Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT StudyAmerican Journal of Transplantation, 2013
- Preformed Complement-Activating Low-Level Donor-Specific Antibody Predicts Early Antibody-Mediated Rejection in Renal AllograftsTransplantation, 2013
- Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor KidneysAmerican Journal of Transplantation, 2012
- Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT StudiesTransplantation, 2010
- Slope of changes in renal function in the first year post‐transplantation and one‐yr estimated glomerular filtration rate together predict long‐term renal allograft survivalClinical Transplantation, 2010
- A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)American Journal of Transplantation, 2010
- HLA-Specific Antibodies Developed in the First Year Posttransplant are Predictive of Chronic Rejection and Renal Graft LossTransplantation, 2009
- Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT TrialTransplantation, 2009
- Costimulation Blockade with Belatacept in Renal TransplantationNew England Journal of Medicine, 2005